-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Major News: Shijiazhuang Sihua Pharmaceutical’s supplemental application for Azithromycin for Injection (0.5 g and 0.25 g) has been approved, making the company the marketing authorization holder for this product.
Category:
发布时间：2021-07-03
【概要描述】
On June 30, Shijiazhuang Sihua Pharmaceutical Co., Ltd. obtained approval from the National Medical Products Administration for a supplemental drug application for injectable azithromycin (0.5 g and 0.25 g), thereby becoming the marketing authorization holder for this product.
On June 30, Shijiazhuang Sihua Pharmaceutical Co., Ltd. obtained approval from the National Medical Products Administration for a supplemental drug application concerning injectable azithromycin (0.5 g and 0.25 g), thereby becoming the marketing authorization holder for this product.
According to available information, this product is a lyophilized powder for injection and is primarily indicated for the treatment of various infections caused by susceptible pathogens. The first-ever approval of this lyophilized powder for injection formulation will help the company diversify its dosage forms, optimize its product mix, accelerate supply-side structural transformation, and further promote high-quality corporate development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091